Inventiva (NASDAQ:IVA) Trading Up 10.1% – Here’s Why

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s stock price was up 10.1% during mid-day trading on Thursday . The company traded as high as $4.25 and last traded at $4.4490. Approximately 345,206 shares traded hands during trading, a decline of 19% from the average daily volume of 426,642 shares. The stock had previously closed at $4.04.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on IVA shares. Wall Street Zen downgraded Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Truist Financial started coverage on Inventiva in a research report on Thursday, March 19th. They set a “buy” rating and a $13.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Inventiva currently has an average rating of “Buy” and a consensus price target of $16.56.

Inventiva Stock Up 6.4%

The stock has a fifty day simple moving average of $5.32 and a two-hundred day simple moving average of $5.40.

Inventiva (NASDAQ:IVA) last issued its earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The business had revenue of $0.01 million during the quarter. Equities research analysts expect that Inventiva S.A. Sponsored ADR will post -0.8 earnings per share for the current year.

Institutional Investors Weigh In On Inventiva

Several hedge funds have recently modified their holdings of the company. Paradigm Biocapital Advisors LP acquired a new stake in shares of Inventiva during the 4th quarter valued at $18,600,000. ADAR1 Capital Management LLC acquired a new stake in shares of Inventiva during the 4th quarter valued at $12,601,000. Millennium Management LLC boosted its holdings in shares of Inventiva by 2,267.7% during the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock valued at $12,334,000 after acquiring an additional 2,540,540 shares in the last quarter. UBS Group AG boosted its holdings in shares of Inventiva by 28,881.6% during the 4th quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after acquiring an additional 2,634,580 shares in the last quarter. Finally, SymBiosis Capital Partners LLC acquired a new stake in shares of Inventiva during the 4th quarter valued at $12,090,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.